Cargando…

Co-benefits of nonpharmaceutical intervention against COVID-19 on infectious diseases in China: A large population-based observational study

Background: Nonpharmaceutical interventions (NPIs) are public health measures that aim to suppress the transmission of infectious diseases, including border restrictions, quarantine and isolation, community management, social distancing, face mask usage, and personal hygiene. This research aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Jianpeng, Dai, Jiya, Hu, Jianxiong, Liu, Tao, Gong, Dexin, Li, Xing, Kang, Min, Zhou, Yan, Li, Yihan, Quan, Yi, He, Guanhao, Zhong, Ruoxi, Zhu, Zhihua, Huang, Qiong, Zhang, Yingtao, Huang, Jianhua, Du, Qingfeng, Li, Yan, Song, Tie, Hu, Wenbiao, Zhong, Haojie, Ma, Wenjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484818/
https://www.ncbi.nlm.nih.gov/pubmed/34611630
http://dx.doi.org/10.1016/j.lanwpc.2021.100282
_version_ 1784577401077891072
author Xiao, Jianpeng
Dai, Jiya
Hu, Jianxiong
Liu, Tao
Gong, Dexin
Li, Xing
Kang, Min
Zhou, Yan
Li, Yihan
Quan, Yi
He, Guanhao
Zhong, Ruoxi
Zhu, Zhihua
Huang, Qiong
Zhang, Yingtao
Huang, Jianhua
Du, Qingfeng
Li, Yan
Song, Tie
Hu, Wenbiao
Zhong, Haojie
Ma, Wenjun
author_facet Xiao, Jianpeng
Dai, Jiya
Hu, Jianxiong
Liu, Tao
Gong, Dexin
Li, Xing
Kang, Min
Zhou, Yan
Li, Yihan
Quan, Yi
He, Guanhao
Zhong, Ruoxi
Zhu, Zhihua
Huang, Qiong
Zhang, Yingtao
Huang, Jianhua
Du, Qingfeng
Li, Yan
Song, Tie
Hu, Wenbiao
Zhong, Haojie
Ma, Wenjun
author_sort Xiao, Jianpeng
collection PubMed
description Background: Nonpharmaceutical interventions (NPIs) are public health measures that aim to suppress the transmission of infectious diseases, including border restrictions, quarantine and isolation, community management, social distancing, face mask usage, and personal hygiene. This research aimed to assess the co-benefits of NPIs against COVID-19 on notifiable infectious diseases (NIDs) in Guangdong Province, China. Methods: Based on NID data from the Notifiable Infectious Diseases Surveillance System in Guangdong, we first compared the incidence of NIDs during the emergency response period (weeks 4–53 of 2020) with those in the same period of 2015–2019 and then compared that with the expected incidence during the synchronous period of 2020 for each city by using a Bayesian structural time series model. Findings: A total of 514,341 cases of 39 types of NIDs were reported in Guangdong during the emergency response period in 2020, which decreased by 50·7% compared with the synchronous period during 2015–2019. It was estimated that the number of 39 NIDs during the emergency response in 2020 was 65·6% (95% credible interval [CI]: 64·0% – 68·2%) lower than expected, which means that 982,356 (95% CI: 913,443 – 1,105,170) cases were averted. The largest reduction (82·1%) was found for children aged 0–14 years. For different categories of NIDs, natural focal diseases and insect-borne infectious diseases had the greatest reduction (89·4%), followed by respiratory infectious diseases (87·4%), intestinal infectious diseases (59·4%), and blood-borne and sexually transmitted infections (18·2%). Dengue, influenza, and hand-foot-and-mouth disease were reduced by 99·3%, 95·1%, and 76·2%, respectively. Larger reductions were found in the regions with developed economies and a higher number of COVID-19 cases. Interpretation: NPIs against COVID-19 may have a large co-benefit on the prevention of other infectious diseases in Guangdong, China, and the effects have heterogeneity in populations, diseases, time and space. Funding: Key-Area Research and Development Program of Guangdong Province
format Online
Article
Text
id pubmed-8484818
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-84848182021-10-01 Co-benefits of nonpharmaceutical intervention against COVID-19 on infectious diseases in China: A large population-based observational study Xiao, Jianpeng Dai, Jiya Hu, Jianxiong Liu, Tao Gong, Dexin Li, Xing Kang, Min Zhou, Yan Li, Yihan Quan, Yi He, Guanhao Zhong, Ruoxi Zhu, Zhihua Huang, Qiong Zhang, Yingtao Huang, Jianhua Du, Qingfeng Li, Yan Song, Tie Hu, Wenbiao Zhong, Haojie Ma, Wenjun Lancet Reg Health West Pac Research Paper Background: Nonpharmaceutical interventions (NPIs) are public health measures that aim to suppress the transmission of infectious diseases, including border restrictions, quarantine and isolation, community management, social distancing, face mask usage, and personal hygiene. This research aimed to assess the co-benefits of NPIs against COVID-19 on notifiable infectious diseases (NIDs) in Guangdong Province, China. Methods: Based on NID data from the Notifiable Infectious Diseases Surveillance System in Guangdong, we first compared the incidence of NIDs during the emergency response period (weeks 4–53 of 2020) with those in the same period of 2015–2019 and then compared that with the expected incidence during the synchronous period of 2020 for each city by using a Bayesian structural time series model. Findings: A total of 514,341 cases of 39 types of NIDs were reported in Guangdong during the emergency response period in 2020, which decreased by 50·7% compared with the synchronous period during 2015–2019. It was estimated that the number of 39 NIDs during the emergency response in 2020 was 65·6% (95% credible interval [CI]: 64·0% – 68·2%) lower than expected, which means that 982,356 (95% CI: 913,443 – 1,105,170) cases were averted. The largest reduction (82·1%) was found for children aged 0–14 years. For different categories of NIDs, natural focal diseases and insect-borne infectious diseases had the greatest reduction (89·4%), followed by respiratory infectious diseases (87·4%), intestinal infectious diseases (59·4%), and blood-borne and sexually transmitted infections (18·2%). Dengue, influenza, and hand-foot-and-mouth disease were reduced by 99·3%, 95·1%, and 76·2%, respectively. Larger reductions were found in the regions with developed economies and a higher number of COVID-19 cases. Interpretation: NPIs against COVID-19 may have a large co-benefit on the prevention of other infectious diseases in Guangdong, China, and the effects have heterogeneity in populations, diseases, time and space. Funding: Key-Area Research and Development Program of Guangdong Province Elsevier 2021-10-01 /pmc/articles/PMC8484818/ /pubmed/34611630 http://dx.doi.org/10.1016/j.lanwpc.2021.100282 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Xiao, Jianpeng
Dai, Jiya
Hu, Jianxiong
Liu, Tao
Gong, Dexin
Li, Xing
Kang, Min
Zhou, Yan
Li, Yihan
Quan, Yi
He, Guanhao
Zhong, Ruoxi
Zhu, Zhihua
Huang, Qiong
Zhang, Yingtao
Huang, Jianhua
Du, Qingfeng
Li, Yan
Song, Tie
Hu, Wenbiao
Zhong, Haojie
Ma, Wenjun
Co-benefits of nonpharmaceutical intervention against COVID-19 on infectious diseases in China: A large population-based observational study
title Co-benefits of nonpharmaceutical intervention against COVID-19 on infectious diseases in China: A large population-based observational study
title_full Co-benefits of nonpharmaceutical intervention against COVID-19 on infectious diseases in China: A large population-based observational study
title_fullStr Co-benefits of nonpharmaceutical intervention against COVID-19 on infectious diseases in China: A large population-based observational study
title_full_unstemmed Co-benefits of nonpharmaceutical intervention against COVID-19 on infectious diseases in China: A large population-based observational study
title_short Co-benefits of nonpharmaceutical intervention against COVID-19 on infectious diseases in China: A large population-based observational study
title_sort co-benefits of nonpharmaceutical intervention against covid-19 on infectious diseases in china: a large population-based observational study
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484818/
https://www.ncbi.nlm.nih.gov/pubmed/34611630
http://dx.doi.org/10.1016/j.lanwpc.2021.100282
work_keys_str_mv AT xiaojianpeng cobenefitsofnonpharmaceuticalinterventionagainstcovid19oninfectiousdiseasesinchinaalargepopulationbasedobservationalstudy
AT daijiya cobenefitsofnonpharmaceuticalinterventionagainstcovid19oninfectiousdiseasesinchinaalargepopulationbasedobservationalstudy
AT hujianxiong cobenefitsofnonpharmaceuticalinterventionagainstcovid19oninfectiousdiseasesinchinaalargepopulationbasedobservationalstudy
AT liutao cobenefitsofnonpharmaceuticalinterventionagainstcovid19oninfectiousdiseasesinchinaalargepopulationbasedobservationalstudy
AT gongdexin cobenefitsofnonpharmaceuticalinterventionagainstcovid19oninfectiousdiseasesinchinaalargepopulationbasedobservationalstudy
AT lixing cobenefitsofnonpharmaceuticalinterventionagainstcovid19oninfectiousdiseasesinchinaalargepopulationbasedobservationalstudy
AT kangmin cobenefitsofnonpharmaceuticalinterventionagainstcovid19oninfectiousdiseasesinchinaalargepopulationbasedobservationalstudy
AT zhouyan cobenefitsofnonpharmaceuticalinterventionagainstcovid19oninfectiousdiseasesinchinaalargepopulationbasedobservationalstudy
AT liyihan cobenefitsofnonpharmaceuticalinterventionagainstcovid19oninfectiousdiseasesinchinaalargepopulationbasedobservationalstudy
AT quanyi cobenefitsofnonpharmaceuticalinterventionagainstcovid19oninfectiousdiseasesinchinaalargepopulationbasedobservationalstudy
AT heguanhao cobenefitsofnonpharmaceuticalinterventionagainstcovid19oninfectiousdiseasesinchinaalargepopulationbasedobservationalstudy
AT zhongruoxi cobenefitsofnonpharmaceuticalinterventionagainstcovid19oninfectiousdiseasesinchinaalargepopulationbasedobservationalstudy
AT zhuzhihua cobenefitsofnonpharmaceuticalinterventionagainstcovid19oninfectiousdiseasesinchinaalargepopulationbasedobservationalstudy
AT huangqiong cobenefitsofnonpharmaceuticalinterventionagainstcovid19oninfectiousdiseasesinchinaalargepopulationbasedobservationalstudy
AT zhangyingtao cobenefitsofnonpharmaceuticalinterventionagainstcovid19oninfectiousdiseasesinchinaalargepopulationbasedobservationalstudy
AT huangjianhua cobenefitsofnonpharmaceuticalinterventionagainstcovid19oninfectiousdiseasesinchinaalargepopulationbasedobservationalstudy
AT duqingfeng cobenefitsofnonpharmaceuticalinterventionagainstcovid19oninfectiousdiseasesinchinaalargepopulationbasedobservationalstudy
AT liyan cobenefitsofnonpharmaceuticalinterventionagainstcovid19oninfectiousdiseasesinchinaalargepopulationbasedobservationalstudy
AT songtie cobenefitsofnonpharmaceuticalinterventionagainstcovid19oninfectiousdiseasesinchinaalargepopulationbasedobservationalstudy
AT huwenbiao cobenefitsofnonpharmaceuticalinterventionagainstcovid19oninfectiousdiseasesinchinaalargepopulationbasedobservationalstudy
AT zhonghaojie cobenefitsofnonpharmaceuticalinterventionagainstcovid19oninfectiousdiseasesinchinaalargepopulationbasedobservationalstudy
AT mawenjun cobenefitsofnonpharmaceuticalinterventionagainstcovid19oninfectiousdiseasesinchinaalargepopulationbasedobservationalstudy